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Summary Covalent linkage of the A chain of ricin to the LICR-LOND-Fib75 monoclonal antibody pro-
duced an immunotoxin, Fib75-SS-ricin A, which demonstrated immunospecific toxicity to human bladder
carcinoma cells in tissue culture (Forrester et al., 1984). The present studies have shown that ricin B chain
potentiates the toxicity of the immunotoxin by two orders of magnitude and also significantly increases the
rate of protein synthesis inhibition. Using immunoelectron microscopy, the receptor-mediated endocytosis and
intracellular routing of the immunotoxin was studied with and without ricin B chain treatment after
immunolocalisation of the conjugate. Fib75-SS-ricin A was internalised by the EJ cells predominantly in
uncoated pits and vesicles and directed to the endosomes. Some degradation of the complex appeared to take
place in multivesicular endosomes at early timepoints and 24 h after internalisation, most of the immunotoxin
was found in lysosomes. Some ricin A chain epitopes were detected in Golgi vesicles. Cells treated with
immunotoxin and ricin B chain endocytosed the complex predominantly in coated pits and coated vesicles.
Using pre-embedding immunoperoxidase techniques, ricin chains were found in the whole Golgi complex and
most of the conjugate escaped lysosomal degradation. Internalised immunotoxin was recycled back to the
plasma membrane in an active form associated with vesicles which appeared to be derived predominantly from
multivesicular endosomes. A similar mode of recycling has recently been reported (McIntosh et al., 1990) for
ricin holotoxin in the same cell line. These observations may explain the potentiating effect of toxin B chains
in the antibody-directed targeting of toxin A chains.
The plant toxin ricin comprises two polypeptide subunits, A
and B, joined by a disulphide bond. It binds to galactose-
containing receptors on the surface of mammalian cells via
its B chain (Olsnes & Pihl, 1973). The toxin subsequently
enters the cells by receptor-mediated endocytosis where its
toxicity is expressed by the inactivation of protein synthesis
following the translocation of the A chain to the cytoplasm.
Hybrid molecules, comprising monoclonal antibodies chemi-
cally coupled to the A chain of plant toxins (immunotoxins)
(Lord et al., 1985) have shown promise in the treatment of
experimental animal tumours and are presently proving to be
increasingly useful alternatives to conventional diffusible
drugs in the treatment of neoplastic disease (Coombes et al.,
1986). Immunotoxins act by terminating protein synthesis in
the target cells. Following binding by antibody recognition of
plasma membrane antigens, conjugates enter cells by recep-
tor-mediated endocytosis (Carriere et al., 1985). After gaining
access to the cytoplasm, the toxin A chain of the conjugate
catalytically cleaves adenine residue 4324 in the 28S ribo-
somal RNA of the 60s ribosomal subunit, irreversibly halting
cellular protein synthesis (Endo & Tsurugi, 1987). Thus the
antibody molecule acts as a surrogate B chain to bring about
immunospecific cell death. The LICR-LOND-Fib75 (Fib75)
monoclonal antibody recognises an HLA class I-related
plasma membrane antigen found in all differentiated human
cells except those of the lymphoid system (Buckman et al.,
1982). Fib75 was covalently linked to the A chain of ricin to
produce an immunotoxin that displayed an immunospecific
and moderate toxicity to target cells in culture, but whicti
was two orders of magnitude less toxic than the parent toxin
(Forrester et al., 1984). A-chain immunotoxins which lack
the galactose-binding B chain polypeptides are often less
cytotoxic than their holotoxin counterparts (Martinez et al.,
1982). Hence different methods have been employed to
potentiate the cytotoxicity of A chain conjugates while main-
taining their immunospecificity. Agents which have been
investigated for their ability to potentiate immunotoxin
activity include the lysosomotropic amines, ammonium chlo-
ride and chloroquine (Ramakrishnan et al., 1989), carboxylic
ionophores such as monensin (Griffin et al., 1987) and the
addition of free or antibody-conjugated toxin B chains fol-
lowing immunlocalisation of the A chain conjugate (Vitetta
et al., 1983; McIntosh et al., 1983). The amines and iono-
phores are thought to increase immunotoxin potency by
causing a rise in the pH of intracellular organelles thereby
interfering with the passage of the immunotoxins from endo-
somes to lysosomes and also by inhibiting degradative
enzyme activity. The aim of this study was to define and
compare the mode of entry and subsequent routing of the
native antibody-labelled Fib75-SS-ricin A chain conjugate in
a human bladder carcinoma cell line with and without the
presence of ricin B chain as a potentiating agent.
Materials and methods
Tissue culture and cytotoxicity assays oftarget cells
The EJ cell line is derived from a human bladder carcinoma
and is routinely maintained in a 1:1 mixture of RPMI 1640/
DMEM (Gibco BRL) supplemented with 5% foetal calf
serum (FCS) (Gibco BRL) in a humidified atmosphere of 8%
CO2 in air at 37°C. For cytotoxicity studies, cells were plated
out in Nunclon 24 well culture plates at 2 x 105 cells per well
and incubated overnight to adhere to the plastic. Triplicate
wells were exposed to log dilutions of conjugates, toxin A
chains, antibodies or antibodies plus A chains for 1 h before
washing the cells three times in PBS to remove unbound
materials. For experiments in which B chain was used as a
potentiating agent, after exposure to the conjugate, the cells
were incubated with ricin B chain at 10-' M for an additional
hour in the presence of 100 mm lactose. The cultures were
then incubated for a further 27 h before pulsing with 3H-
leucine at 1 jsCi per well for 17 h. At the end of this period,
the cell monolayers were washed three times with PBS to
remove the unincorporated isotope, fixed twice in 5% tri-
chloracetic acid and dried following a methanol wash. The
contents of each well were solubilised in 200pl 1 M NaOH
for 1 h at 37°C and protein synthesis was determined by
scintillation counting 150 tLI of cellular digest. The results are
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expressed as percentages of the levels of synthesis in appro-
priate control cultures. In experiments where the timecourse
of protein synthesis inhibition was assayed, cells were ex-
posed to either ricin, Fib75-SS-ricin A or conjugate plus ricin
B chain for 1 h. For the earliest (1 h) timepoints, 5 ItCi
3H-leucine of a higher specific activity than that used for the
standard assays (120-190 Ci mMol ') was added to the cul-
tures exposed to the treatments in leucine-free medium. For
subsequent timepoints, the cells were washed free of toxin,
conjugate and conjugate plus B chain/lactose and incubated
in serum-free medium. Cultures were then pulsed for 20 min
before harvesting as described above. For ultrastructural
studies 4 x I05 cells were plated out (in triplicate) overnight
in 30 mm Petri dishes (Sterilin) to allow the cells to adhere
before processing. A mouse bladder carcinoma cell line
MB49 was used as a specificity control.
Antibodies
Gold conjugates, anti-rabbit (GIO) and anti-mouse (G5)
IgGs were obtained from Janssen (Belgium). A polyclonal
rabbit anti-ricin antibody was a gift from Dr D.C. Edwards
(ICR, London, UK). It was raised against ricin toxoid and
assayed for affinity for ricin holotoxin and A and B chains by
an Ouchterlony assay. Fib75-SS-ricin A was prepared as
described by Forrester et al. (1984). Briefly, the covalent
linkage of ricin A chain to the Fib75 monoclonal antibody
was achieved by first reacting the immunoglobulin with N-
succinimidyl-3-(2-pyridyldithio) propionate (SPDP) under
conditions that gave approximately two pyridylsulphide
groups per molecule of IgG. The derivatised IgG was then
allowed to react with a 2-fold molar excess of free A chain
overnight at room temperature. The reaction mixture was
resolved by gel filtration on Sephacryl S-200. Fractions cor-
responding to a 1:1 conjugate of antibody with A chain were
used for this study. The conjugate was found to contain
some free antibody as well as species singly and multiply
substituted with toxin A chain.
Prepartion ofricin B chain
Essentially this method involves cleavage of the holotoxin
disulphide bond while the toxin is immobilised on an agarose
matrix via the binding site of the B chain. One hundred to
150 mg of the toxin was loaded onto an acid-treated Sep-
harose 4B column (bed volume 25 ml) equilibrated with
0.1 M phosphate buffer, pH 8.0, containing 1 mM EDTA. The
column was then washed with four bed volumes of running
buffer to elute both non and partially bound material. Runn-
ing buffer (15 ml) containing 5% 2-mercaptoenthanol was
loaded and the flow of buffer was then stopped and the
column allowed to stand for 2h to allow cleavage of the
disulphide linkages. The toxin A chain was eluted leaving
the B chain and uncleaved toxin still bound to the column.
The B chain was eluted from the column with 500 mM galac-
tose, 100 mM Na2PO4, 5% 2-mercaptoethanol, 150 mM NaCl
pH 8.8. The eluted protein peak was dialysed against the
running buffer for ion exchange chromatography. A column
of LKB CM-Trisacryl (40 ml bed volume) was equilibrated
with 10mM phosphate buffer at pH 6.0 containing 100 mM
galactose and 0.5% 2-mercaptoethanol and set to run at
14 ml h-' collecting 4 ml fractions. The dialysed B chain was
applied to the column and the breakthrough peak containing
the unbound fraction was collected.
The B chain was dialysed against the running buffer for
chromatofocussing. A column of PBE94 (bed volume 30 ml)
was equilibrated with 0.025 M histidine/HCl buffer at pH 6.2
containing 20 mM galactose and approximately 50 mg of dia-
lysed B chain was applied to the column. The column was
washed with 2-3 column volumes and a pH gradient formed
by eluting with 12 column volumes of 1/8 dilution of Poly-
buffer 74 at pH 4.0 containing 20 mM galactose. The diluent
used was distilled water and 1.0 M HCI to adjust the pH of
the polybuffer. Pure B chain was focussed at its PI of 4.8.
Ultrastructural immunocytochemistry
The target cells were incubated with 10-7 M Fib75-SS-ricin A
at 4°C for 15 min in medium containing FCS. The cells were
then washed three times in cold phosphate buffered saline
(PBS). In experiments in which ricin B chain was used
following immunotoxin binding, 10-7M ricin B chain was
added to the Fib75-SS-ricin A-labelled cells in the presence of
100mM lactose for an additional 15 min at 4°C. At the end
of the incubation the cells were washed three times in PBS.
The antibody component of the conjugate was labelled by
incubation with a 1/10 dilution of a goat anti-mouse IgG-G5
conjugate (Janssen) for 15 min at 4°C. The cells were then
washed three times in PBS to remove the unbound label. The
A chain of the toxin was labelled by a 15 min incubation
with a polyclonal rabbit anti-ricin antibody (22;tgml-')
followed by a 1/10 dilution of GIO-labelled goat-anti-rabbit
conjugate. To follow the fate of ricin B chain in the cells the
B chain was bound to the cell surface at 4°C for 15 min at
10- M and the cells were washed as described above. The
surface-bound ligand was then labelled with a rabbit anti-
ricin polyclonal antibody (22lLgml-'). Labelling was com-
pleted with the addition of a goat anti-rabbit gold conjugate
(GIO). Preparations for the identification of plasma mem-
brane bound ligands were fixed in 1% glutaraldehyde: 0.08 M
cacodylate buffer pH 7.2 for 1 h at room temperature and
processed as described below. Other cells were re-incubated
in serum-containing medium at 37°C for various times up to
20 h to allow the internalisation of the labelled complex and
then washed and fixed as described above.
Processing ofcellsfor electron microscopy
After the first fixation, all cells were washed in cacodylate
buffer and post fixed in 1% OS04 in the same buffer for a
further hour. The monolayers were then washed with distilled
water for 30 min and dehydrated in a graded series of
alcohols. The cells were floated off the surface of the Petri
dishes with propylene oxide. The cell pellet was centrifuged
at 1,000 r.p.m. and embedded in Araldite (EMScope). Ultra
thin sections were cut using a diamond knife, stained in lead
citrate and examined in a Phillips EM-100 electron micro-
scope at an accelerating voltage of 80 Kv.
Quantification
Ten randomly selected cells were photographed at a mini-
mum magnification of 10,000 x. The 10 nm gold particles in
subcellular compartments labelling ricin chains were counted
and expressed as a percentage of the total particle number at
a given time point. The total particle number per cell at each
time point exceeded 300.
Binding and internalisation ofnative ligands
Immunotoxin or B chain-treated immunotoxin was bound to
the cell surface as described above and internalisation of
ligands was allowed to continue for different time periods.
The cells were washed in PBS and fixed in 2% paraformal-
dehyde/PBS for 30 min. The cells were then washed in PBS
and permeabilised with 0.05% saponin/PBS (wt/v) for 45 min
at room temperature after which the cells were washed exten-
sively in PBS. Intracellular ricin A and B chains were
detected by a 1 h incubation of the monolayer with rabbit-
anti-ricin IgG (22iLgml-') in PBS containing 0.05% saponin
followed by extensive washes with PBS and a second anti-
body incubation with swine-anti-rabbit IgG-peroxidase con-
jugate (1/15 dilution in PBS/0.05% saponin). After three
washes in PBS the cell monolayers were incubated for 30 min
at room temperature in 2 ml PBS containing 1 mg diamino-
benzidine (DAB) and 2iLl H202 (15%). After several PBS
washes the cell monolayer was fixed in OS04 and processed
for electron microscopy as described above. Fib75 mono-
clonal antibody, either free or conjugated, was detected by a
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jugate at a 1:25 dilution in PBS/0.05% saponin. The cells
were then processed as described previously. Preparations
lacking the primary antibody served as negative controls for
ricin A chain detection. For Fib75 controls, a rabbit-anti-
goat IgG-peroxidase conjugate was used. Additionally, a
mouse bladder carcinoma cell line, MB49 was used as specifi-
city control.
Results
Plasma membrane localisation ofgold-labelled ligands at 4°C
The immunotoxin was found in a patchy distribution on the
plasma membrane appearing as a mixutre of 5 and 1OnM
gold particles (monoclonal antibody and ricin A chain
respectively) (Figure la, b). The Fib75-SS-ricin A with assoc-
iated ricin B chain was found localised in coated pits as has
been observed previously for ricin holotoxin (Van Deurs et
al., 1986; McIntosh et al., 1990) as well as in discrete areas of
the plasma membrane (Figure 2a). Fib75 antibody was seen
as fairly evenly distributed label on the plasma membrane
but was absent from coated areas. In the presence of 100 mM
lactose no binding of ricin B chain to the cell surface was
seen (data not shown). B chain added to cell monolayers
without Fib75-SS-ricin A and in the absence of 100 mM
lactose bound to the plasma membrane and was seen as
small clusters of GIO gold label. No plasma membrane label-
ling was observed when either the MB49 mouse tumour was
treated in place of the EJ cells or when the primary anti-
bodies were omitted from the labelling procedures.
Internalisation ofgold-labelled ligands
After 5 min at 37°C the immunotoxin molecules were trans-
ferred to cytoplasmic endosomal compartments. The immuno-
toxin complex without B chain entered the cell exclusively in
uncoated pits and vesicles (Figure lc) while immunotoxin
bearing ricin B chain entered cells predominantly (83%) in
coated pits and coated vesicles, in a manner previously des-
cribed for ricin holotoxin (Figure 2a and b). Components of
Fib75-SS-ricin A were seen occasionally separated in early
endocytic compartments suggesting a certain degree of labi-
lity of the conjugate.
In treatments using free B chain, the B chain was seen in
the endosomes; some still remained on the plamsa mem-
brane. Thirty to 60 min after internalisation of the immuno-
toxin complexes the most heavily labelled compartments were
the endosomes and to a lesser extent the multivesicular endo-
somes; some label was also observed in secondary lysosomes
(Figures 3a, b, c and 4a, b, c). All of these compartments
contained both G5 and GIO gold particles indicating no
further dissociation of the conjugate. In addition to the
continuous presence of label at the plasma membrane, cells
treated with Fib75-SS-ricin A plus ricin B chain started to
generate vesicles labelled with both 5 nm and 1Onm gold
particles which appeared at the cell surface; these vesicles
were absent in cells treated with either Fib75-SS-ricin A
alone or ricin B chain alone (McIntosh et al., 1990). In cells
internalising the immunotoxin-gold complex the gold parti-
cles were found to be aggregated in some multivesicular
endosomes indicating that degradation of the protein com-
ponent of the complex was taking place (Figure 3d). Aggre-
gation of gold label in multivesicular endosomes at this
timepoint was not seen in cells treated with immunotoxin
plus ricin B chain and was not observed as a consequence of
ricin toxicity in a previous study (Figure 4c). Twenty-four
hours after internalisation of the complex the Fib75-SS-ricin
A-treated cells contained the 5 and 1Onm gold complexes
mostly in secondary lysosomes (Figure 5). Cells treated with
the immunotoxin plus ricin B chain showed signs of cellular
damage and contained far less lysosome-associated gold label
(Figure 6b); most of the label was found extracellularly,
mainly associated with plasma membrane vesicles (Figure
6a). In control samples both Fib75 antibody and ricin B
Figure 1 Fib75-SS-ricin A immunolocalisation at 4°C on EJ
cells. G5 gold label represents Fib75 and GIO, ricin epitopes. a,
label is localised in a well-defined area. Bar = 0.1 s; b, Coated pit
is unlabelled. Bar = 0.1 t; c, Fib75-SS-ricin A, 5 min after incu-
bation at 37°C. Note the presence of label at the cell surface and
in uncoated pit/vesicles. There is an apparent separation of G5
and GIO particles in certain vesicles. There is an apparent separa-
tion of G5 and G10 particles in certain vesicles. Bar = 0.1 t.
chain were found in the lysosomes 24 h after internalisation
and no cell surface labelling remained.
Quantification ofgold label
Morphometric analysis (based on calculations of 3,000 par-
ticles per sample) of the amount of GIO label (ricin A chain)
found in cellular compartments showed significant differences
between the internal distribution of Fib75-ricin A chain com-
plexes with and without ricin B chain. It should be noted
that ricin B chain may also have been labelled with the GIO
since the polyclonal antibody used was raised against ricin
holotoxin. The immunotoxin and B chain complex was found658 J. TIMAR et al.
Figure 2 a, Localisation of Fib75-SS-ricin A associated with ricin B chain, at 4°C on EJ cells. Note the labelled membrane areas
as well as the coated pit. Bar = 0.1 i. b, Cells after incubation with conjugate plus B chain at 37°C for 5 min. The coated vesicle
contains both the G5 and G10 label. Bar = 0.1 .
Figure 4 Internalisation of Fib75-SS-ricin A + B chain for 30
min. a, Labelled endosome. Bar= 0.1 t. b, Labelled multivesi-
cular endosome. Bar = 0.1 t. c, Note lack of aggregated gold
label in multivesicular endosome. Bar = 0.1 t.
Figure 3 Internalisation of Fib75-SS-ricin A at 37'C for 30 mmn.
a,b Endosomes containing both G5 and G10 label. Bar = 0.1 p. c,
Multivesicular endosome labelled with G5 and G10. Bar = 0.1 .
d, After I h at 3TC, Fib75-SS-ricin A in multivesicular endo-
somes in an aggregated form. Bar =0. lIt.
to enter the cells more slowly than the immunotoxin alone
(Figure 7a). Once inside the cell both types of complex were
found in acidic compartments but the levels found at 10-60
min after internalisation were greater for the immunotoxin
alone than for the B chain-treated complex (Figure 7b).
There was a significant difference between the amount of
labelled Fib75-SS-ricin A and the immunotoxin with B chain
found in the lysosomes at times later than 30 min after
uptake by the cell (Figure 7c). Approximately 80% of the
cell-associated Fib75-SS-ricin A was found in the lysosomes
at 24 h compared with only 15% of the conjugate plus B
chain.
Internalisation ofthe native (unlabelled) ligands
The preceding experiments clearly demonstrated differences
in the mode of internalisation and fate of the two conjugatesB CHAIN RE-ROUTING OF IMMUNOTOXINS 659
Figure 5 Fib75-SS-ricin A 24 h after internalisation by EJ cells at 37C. Note the aggregated label in secondary lysosomes.
Bar = 1.0p.
Figure 6 Fib75-SS-ricin A + B chain 24 h after internalisation at 37°C. a, The plasma membrane and associated vesicles are heavily labelled with both G5 and GI0. The cells infrastructure is altered due to the toxic effects of the conjugate. Bar = 1.0A. b, A secondary lysosome containing aggregated label. Bar = 1.0 p.
(+ and - B chain). However it could be argued that their
fates were influenced by the labelling method employed (gold
particles). Therefore in the following experiments we have
investigated the mode of internalisation of the unlabelled
immunotoxins using peroxidase-labelled antibodies and per-
meabilised cells. The Fib75-SS-ricin A chain conjugate was
seen to enter cells exclusively via uncoated pits and uncoated
vesicles similarly to the gold-labelled conjugate. Later it was
found in endosomes (Figure 8a). After 1 h of internalisation
A chain was detected in Golgi-associated vesicles but none was
detected in parallel membranes of the Golgi cisternae (Figure
8b). At later timepoints most of the immunotoxin was found
in secondary lysosomes (Figure 8c). Fib75-SS-ricin A com-
plexed with ricin B chain bound to the plasma membrane at
4°C in a manner similar to Fib75-SS-ricin A alone, but after
warming to 37°C was seen to localise spontaneously in coated
pits, enter the cells predominantly in coated vesicles and gain
access to the endosomal system (Figure 9a). At timepoints
later than 30 min, label was found in multivesicular endosomes
(Figure 9c) and in the parallel membranes of the Golgi com-
plex (Figure 9b). At later timepoints, label was found on
extracellular vesicles associated with the plasma membrane in a
manner identical to that seen with the gold-labelled Fib75-SS-
ricin A + ricin B chain complex. Very little immunotoxin with
B chain was found in the secondary lysosomes when the native
ligands were stained with peroxidase. Figure 10 summarises
our observations of the intracellular trafficking of Fib75-SS-
ricin A (panel a) and Fib75-SS-ricin A treated post-
immunolocalisation with ricin B chain (panel b). No labelling
was observed when the anti-rabbit-goat IgG-peroxidase con-
jugate was substituted for the swine-anti-rabbit peroxidase
conjugate or when the MB49 mouse cell line was given iden-
tical treatments in place of the EJ cell line.
Cytotoxicity studies
Table I shows the toxicity of I h exposures of the EJ cells to
the ricin A chain conjugate with and without ricin B chain
(in the presence of 100 mM lactose) as a second stage reagent.
It can be seen that the ricin B chain treatment in conjunction
with Fib75-SS-ricin A increased the toxicity of the conjugate
by two orders of magnitude, resulting in a toxic effect similar
to that of ricin holotoxin. A I h treatment of the cells with
ricin B chain alone did not elicit an inhibitory response.
Figure 11 compares the timecourse of protein synthesis
inhibition in EJ cells by Fib75-SS-ricin A with and without
ricin B chain treatment. A maximum of 90% inhibition was
achieved 24 h after treatment with the conjugate alone. The
tl/2 (time taken to inhibit protein synthesis by 50%) was
12.5 h. Treatment of cells with Fib75-SS-ricin A and ricin B
chain resulted in total inhibition of protein synthesis and a
tl/2 of 1.5 h, a figure comparable with that of ricin holotoxin
(tl/2= 1 h).
Discussion
The present study has demonstrated that the moderate cyto-
toxic effects of Fib75-SS-ricin A can be enhanced signifi-
cantly by a post-immunolocalisation treatment with ricin B
chain. In addition, the rate of protein synthesis inhibition is
markedly increased in the presence of the B chain. These
considerations led us to speculate on the mode of internalisa-
tion of the Fib75-SS-ricin A conjugate in the absence and
presence of ricin B chain and to determine whether there
might be a correlation between the pattern of internalisation
and the levels of toxicity seen in the target cells. It seems660 J. TIMAR et al.
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Figure 7 Quantitative analysis of the internalisation of ricin
epitopes into EJ cells. (0) Fib75-SS-ricin A; ( + ) Fib75-SS-ricin
A + ricin B chain. a, Label associated with the cell surface; b,
Label associated with intracellular acidic compartments (endo-
somes and multivesicular endosomes); c, Lysosomal labelling (see
Materials and methods).
likely that the endocytic route taken by the conjugate might
play an important role in determining the intracellular orga-
nelle from which ricin A chain enters the cytoplasm and
hence the kinetics ofprotein synthesis inhibition and the level
of the resultant toxicity.
The present study of the internalisation of the native and
gold-labelled conjugates following binding to the target cells
at 4°C revealed that the intracellular trafficking of the two
types was very similar. Both the native and gold-labelled
conjugate bound to the plasma membrane and entered the
cells predominantly by the uncoated vesicle pathway and
were seen in the endosomal compartments, in multivesicular
endosomes and at later times in secondary lysosomes. During
the internalisation and routing of the conjugate both major
components of the complex, epitopes of the monoclonal
antibody and the ricin A chain, were found together in
almost all intracellular compartments involved. A low level
ofsegregation ofthe two target ligands was observed in some
early endocytic compartments close to the plasma membrane.
Only the native A chain of Fib75-SS-ricin A was seen to
reach the Golgi-associated vesicles but not the Golgi cister-
nae. This may be due to the increased size of the immuno-
toxin-gold complex compared with the molecular size of the
native immunotoxin. The presence of both sizes of gold
particles in the majority of intracellular organelles indicates
Figure 8 Internalisation of Fib75-SS-ricin A (for 1 h) by EJ
cells. Detection of ricin epitopes by an indirect peroxidase
method. a, The lumenal membrane of the endosome is clearly
labelled; b, Golgi zone. Note the absence of ricin chains in the
Golgi cisternae but the presence of label in Golgi-associated
vesicles. Bar = 0.1 ; c 24 h after internalisation of the conjugate.
Ricin epitopes are found in secondary lysosomes. Bar = 0.1 .
the stability of the conjugates disulphide linkage even in
acidic compartments. Separate administration of Fib75 anti-
body and ricin B chain to the cells also resulted in the
eventual passage of these ligands to the lysosomes. The
routing of a monoclonal antibody and a ricin A chain
immunotoxin to the lysosomes has also been reported by
Calafat et al. (1988) who also observed that the immunotoxin
remained intact until it reached the lysosomal compartment.
In the present study although no apparent recycling of the
conjugate to the cell surface was seen to occur in cells treated
with Fib75-SS-ricin A, Fib75 antibody or ricin B chain alone,
cells treated with immunotoxin plus B chain generated label-
led vesicles at the cell surface (using both the gold and
peroxidase labels) that seemed to derive from multivesicular
endosomes. In a previous study of the intracellular trafficking
of ricin holotoxin (McIntosh et al., 1990) we have observed
and measured ricin being returned to the cell surface assoc-
iated with vesicles being released to the extracellular space
from multivesicular endosomes. Subsequently this material
was shown to be toxic in cytotoxicity assays (McIntosh,
unpublished data). Exocytosis of vesicles from multivesicular
endosomes during the cellular cycling of ligands is similar to
that described for the release of the transferrin receptor by
reticulocytes (Pau et al., 1985).
The other major difference observed between the intracel-
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Figure 10 Schematic representation of immunotoxin internalisa-
tion by EJ cells. a, Fib75-SS-ricin A. The A chain immunotoxin
entered the cells via the uncoated pit/uncoated vesicle pathway. It
was then seen aggregated in multivesicular endosomes prior to its
degradation in secondary lysosomes; b, Fib75-SS-ricin A assoc-
iated with ricin B chain. The immunotoxin complexed with ricin
B chain was seen to enter the cells predominantly via the coated
pit/coated vesicle pathway. It appears more stable as judged by
its lack of aggregation in the multivesicular endosomes. Ricin
epitopes were detected in the Golgi-associated vesicles and cister-
nae and appeared to recycle from the cell in multivesicular
endosomes. PM - plasma membrane; UCP - uncoated pit; CP -
coated pit; ES - endosome; CV - coated vesicle; UCV - uncoated
vesicle; MVES - multivesicular endosome; G - Golgi; LY -
lysosome.
1 ^
Figure 9 Internalisation of Fib75-SS-ricin A+ ricin B chain.
Detection of ricin epitopes in situ by an immunoperoxidase
method. a, 30 min after internalisation at 37C, note the heavy
labelling of endosomes. Bar= 0.1 ; b 60 min after internalisa-
tion, there is a strong reaction throughout the Golgi system as
well as at the cell membrane. Bar = 0.1lt; c, 24 h after inter-
nalisation, the multivesicular endosomes, plasma membrane and
the associated vesicles are heavily labelled. Bar = 0.1 s.
lular trafficking of immunotoxin with and without ricin B
chain was the appearance of ricin chains in the Golgi com-
plex in cells treated with Fib75-SS-ricin A and B chain.
Recent reports (Van Deurs et al., 1986; 1988) have implicated
the Golgi as the organelle from which ricin A chain is
transported to the cytoplasm and thus mediates its cytotoxic
effects. If ricin chains more often gain access to the ribo-
somes from this organelle, the re-routing of immunotoxins to
the Golgi by ricin B chain may be responsible for the
enhanced cytotoxic effects seen in the presence of ricin B
chain. In addition, the recycling of immunotoxin to the cell
surface would result in the re-exposure of the cell to further
toxin attack. It is probable that the toxin chains can gain
access to the cytoplasm from a variety of organelles but may
do so less efficiently than from the Golgi complex. Certainly
agents that prevent immunotoxin from entering the lyso-
somes, such as monensin and ammonium chloride, thereby
increasing (by this mechanism alone) the exposure time of the
cell to a cytotoxic agent, are likely to potentiate its toxic
effects. The apparent protection of an A chain immunotoxin
from lysosomal delivery and hence degradation has also been
c
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Figure 11 Time course of inhibition of protein synthesis in EJ
cells by Fib75-SS-ricin A (@) and Fib75-SS-ricin A + ricin B
chain/l00 mM lactose (0). Each point represents the mean of
three determinations. All standard errors are less than 10%.
Table I
Treatment Exposure ID50
Fib75-SS-ricin A 1 h 7 x 10-° M
Ricin B chain I h no toxic effect
Fib75-SS-ricin A + ricin B chain 30 + 30 (min) 7 x 10-12 M
Ricin holotoxin I h 8 x 10-12 M
reported by Manske et al. (1989) who compared the intracel-
lular behaviour of an A chain conjugate with that of a
holotoxin conjugate.
The route and rate of internalisation of an immunotoxin
will be largely determined by the nature of the antigen to
which it binds. However, when the Fib75-SS-ricin A chain
conjugate is complexed with B chain (Fib75-SS-ricin A-B),
the cell surface galactose-containing receptor might be the
preferred vehicle for internalisation of the conjugate, partic-
ularly if the binding affinity of the monoclonal antibody for
the target antigen is low. When lactose is removed from the
culture system, the B chain although in association with the
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A chain of the immunotoxin may be able to bind to galac-
tose-containing receptors on the cell surface and thereby
mediate the entry of the immunotoxin to the cell via the
coated pit/coated vesicle pathway.
To summarise, the major differences observed in this study
between the behaviour of the immunotoxin with and without
ricin B chain were that in the presence of B chain: (i) ricin
chains appeared in the entire Golgi complex and were not
restricted to Golgi-associated vesicles; (ii) the stability of the
conjugate in multivesicular endosomes was increased; and
(iii) the complex reappeared at the plasma membrane on
vesicles that seemed to be produced from the multivesicular
endosomes of A chain intoxicated cells. It appears that the
conjugate associated with ricin B chain gains access to the
cell, is routed intracellularly and recycled to the plasma
membrane in a similar manner as described for native ricin
holotoxin (McIntosh et al., 1990; 1984). The differences in
the patterns of cellular trafficking of immunotoxin containing
ricin A chain, with and without associated ricin B chain may
well account for the very marked differences in cytotoxic
effects observed.
We thank David Robertson for help with electron microscopy and
Margaret Williamson for typing this manuscript.
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